Loading candles…
Lyka Labs Ltd, incorporated in 1976 and headquartered in Mumbai, India, operates in the pharmaceutical industry. The company develops, manufactures, and markets pharmaceutical products that include finished dosages, injectables, lyophilized injectables, and topical formulations. Lyka Labs maintains a manufacturing facility in Ankleshwar, Gujarat, and a Research & Development center in Mumbai. It specializes in delivery systems such as lyophilization (freeze-drying) to support its product offerings. The company's operations are focused within India.
This page is a live market overview for LYKA LABS LTD. (LYKALABS) on the NSE. As a listed security, LYKA LABS LTD. is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for LYKALABS before placing trades on tick2trade.
As of the latest feed, LYKALABS last traded at ₹86.7 on NSE, up ₹0 (0.00%) from the previous close of ₹86.7. Today's session range is ₹85.99 – ₹86.7, against a 52-week band of ₹44.1 – ₹101.9. Traded volume today stands at 10.23K shares.
The overview consolidates an interactive price chart with multiple time ranges, five-level bid and ask depth, recent market headlines, upcoming corporate events for LYKALABS in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether LYKALABS is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for LYKA LABS LTD. before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in LYKALABS. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated LYKALABS option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 10 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 25 May 2026 |
| Other | To consider other business matters | 31 Mar 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 29 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and other business matters | 12 Nov 2025 |
| Other | To consider other business matters for redemption of Preference Shares and Appointment of Company Secretary and Compliance Officer | 29 Sep 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 1 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and other business matters | 26 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.